Flow Cytometry In Oncology And Immunology Market Growth Trends Analysis And Dynamic

By Author: bis research
Total Articles: 68
Comment this article

With the increasing burden of cancer, the demand for flow cytometry has increased worldwide. Flow cytometry provides quick and effective data collection from a heterogenous mixture of fluids. This is primarily due to the extensive adoption of flow cytometry-based products for improving the diagnosis and screening of cancer, particularly hematological malignancies. Additionally, manufacturers are significantly investing in research and development (R&D) to expand their respective product portfolios by developing multiparametric and next-generation flow cytometry solutions for cancer diagnostic testing

The global flow cytometry in oncology and immunology market was valued at $1,653.2 million in 2021 and is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032. The market is driven by factors such as the increasing burden of cancer, expansion of applications in flow cytometry for research activities, innovation in flow cytometry leading to the use of next-generation flow cytometers, and the increasing use of flow cytometry in the identification and diagnosis of ...
... immune-deficiency diseases.

View Report - Flow Cytometry in Oncology and Immunology Market

Recent Developments in the Global Flow Cytometry in Oncology and Immunology Market

• In February 2022, Becton, Dickinson and Company acquired Cytognos, S.L. Through this acquisition, the company expanded its flow cytometry portfolio and gained the expertise of ~80 scientists and professionals at Cytognos S.L.
• In September 2022, Becton, Dickinson and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.
• In September 2021, Beckman Coulter, a wholly owned subsidiary of Danaher Corporation, launched its new CytoFLEX flow cytometry platform, which is expected to open new avenues for cancer researchers with respect to single-cell analysis. This new system launched by the company offers powerful analytical performance in a benchtop instrument, which offers high sensitivity.
• In February 2021, Thermo Fisher Scientific Inc. acquired the cell sorting technology assets of Propel Labs, which is expected to broaden Thermo Fisher's flow cytometry and cell analysis portfolio.
• In December 2020, Thermo Fisher Scientific Inc. acquired Phitonex, Inc., a pioneer in the field of spectral dye platforms for high-resolution biological applications, including oncology and immunology. With the acquisition of the company, Thermo Fisher Scientific Inc. is expected to offer greater flow cytometry capabilities to meet evolving customer demands for cell and protein analysis research.
• In January 2020, Luminex Corporation acquired Merck's flow cytometry business portfolio for $75 million, further enabling the company to effectively enhance its existing offerings related to flow-based detection instruments. The company's newly acquired FCM portfolio includes Guava and Amnis product portfolios.

Market Segmentation:

Segmentation 1: by Offering
• Products
o Instruments
o Reagents and Consumables
o Software
• Services

The global flow cytometry in oncology and immunology market (by offering) is expected to be dominated by the products segment.

Segmentation 2: by Technology
• Cell-Based Flow Cytometry
• Bead-Based Flow Cytometry

The global flow cytometry in oncology and immunology (by technology) is expected to be dominated by the cell-based flow cytometry segment.

Segmentation 3: by Type
• Immunology
• Oncology

The global flow cytometry in oncology and immunology market (by type) is dominated by the oncology segment.

Segmentation 4: by Application
• Translational Research
• Clinical Research

The global flow cytometry in oncology and immunology market (by application) is dominated by the translational research segment.

Segmentation 5: by End User
• Hospitals, Diagnostic Laboratories, and Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others

The global flow cytometry in oncology and immunology market (by end user) is dominated by the hospitals, diagnostic laboratories, and reference laboratories segment.

Segmentation 6: by Region
• North America - U.S., Canada
• Europe - Germany, France, U.K., Italy, Spain, Netherlands, Rest-of-Europe
• Asia-Pacific - Japan, China, India, Australia, South Korea, Singapore, Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World

The global flow cytometry in oncology and immunology market (by region) is dominated by the North America segment.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the players in this market are:

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Cytek Biosciences, Inc.
• Danaher Corporation
• DiaSorin S.p.A (Luminex Corporation)
• Enzi Biochem Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Miltenyi Biotec
• NeoGenomics Laboratories, Inc.
• OPKO Health, Inc.
• Sony Group Corporation
• Thermo Fisher Scientific Inc

Get Free Sample Report - https://bisresearch.com/requestsample?id=1399type=download

BIS Related Studies

Global Flow Cytometry in Oncology Market